Unusual 11 Mid-Day Movers 8/11: (KURA) (NYMX) (AEMD) Higher; (QHC) (SHLM) (IDN) Lower

August 11, 2016 12:55 PM EDT
Get Alerts QHC Hot Sheet
Trade QHC Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Quorum Health Corporation (NYSE: QHC) 51.6% LOWER; reported Q2 results. Net operating revenues for the three months ended June 30, 2016 totaled $529.7 million compared to $538.4 million for the same period in 2015. Net loss attributable to Quorum Health Corporation for the three months ended June 30, 2016 was $(245.1) million, or $(8.63) per share, compared with net income attributable to Quorum Health Corporation of $1.4 million, or $0.05 per share, for the same period in 2015. The net loss attributed to the impairment charge for the three months ended June 30, 2016 was $(216.1) million or $(7.61) per share.

Kura Oncology (Nasdaq: KURA) 33.7% HIGHER; reported Q1 EPS of ($0.36), $0.01 better than the analyst estimate of ($0.37). In the company’s Phase 2 trial of tipifarnib in HRAS mutant solid tumors, positive clinical activity, including objective responses, has been observed in patients with head and neck squamous cell carcinomas and patients with salivary gland cancer. Based on these responses, enrollment will be expanded to an additional seven patients.

Nymox Pharmaceutical Corporation (Nasdaq: NYMX) 32.0% HIGHER; announces major progress in the evidence for the safety and efficacy of fexapotide, the Company's Phase 3 drug in the final stages of development for prostate enlargement (BPH) and for low grade prostate cancer. Fexapotide has completed 2 long-term large Phase 3 BPH studies? in the U.S. No other new prostate drug injectable currently in development has previously succeeded in enrolling and completing a fully U.S. study close to the size of either of Nymox’s 2 long-term studies.

Aethlon Medical, Inc. (Nasdaq: AEMD) 28.0% HIGHER; announced that its researchers have completed in vitro studies that demonstrate the rapid capture of Zika virus by the Aethlon Hemopurifier. The Hemopurifier® is a leading broad-spectrum treatment countermeasure against viral pathogens that are untreatable with or resistant to antiviral drug therapies.

A. Schulman, Inc. (Nasdaq: SHLM) 26.7% LOWER; announced that it has lowered its full-year 2016 adjusted net income guidance range to $1.90 to $1.95 per diluted share reflecting deteriorating market conditions facing the industry in the Company's largest regions in the U.S. and Europe. (The Street was looking for FY16 EPS of $2.56.)

Intellicheck Mobilisa (NYSE: IDN) 23.3% LOWER; reported Q2 EPS of ($0.19), versus ($0.12) reported last year. Revenue for the quarter came in at $940 thousand, versus $2.3 million reported last year.

Alpha & Omega (Nasdaq: AOSL) 21.3% HIGHER; reported Q4 EPS of $0.14, $0.09 better than the analyst estimate of $0.05. Revenue for the quarter came in at $91.4 million versus the consensus estimate of $87.5 million.

Aegean Marine (NYSE: ANW) 19.7% HIGHER; reported Q2 EPS of $0.32, $0.09 better than the analyst estimate of $0.23. Revenue for the quarter came in at $987.6 million versus the consensus estimate of $899.63 million.

Energy Focus (Nasdaq: EFOI) 18.3% LOWER; reported Q2 EPS of ($0.34), $0.25 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $7.1 million versus the consensus estimate of $11.07 million. Energy Focus sees Q3 2016 revenue of $8-10 million, versus the consensus of $14.7 million.

Avinger, Inc. (Nasdaq: AVGR) 18.0% LOWER; announced the pricing of its public offering of 8,572,000 shares of its common stock at a price to the public of $3.50 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to 1,285,800 additional shares of its common stock. The Company expects to close the offering on August 16, 2016, subject to customary closing conditions.

Macy's (NYSE: M) 16.7% HIGHER; reported Q2 EPS of $0.54, $0.09 better than the analyst estimate of $0.45. Revenue for the quarter came in at $5.87 billion versus the consensus estimate of $5.74 billion. Macy's outlined a series of initiatives to drive profitable growth, enhance shareholder value and strengthen Macy’s as America’s preferred omnichannel shopping destination. As part of this strategy, the company intends to close approximately 100 Macy’s full-line stores (out of a current portfolio of 728 Macy’s stores, including 675 full-line locations).

To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Related Entities

Unusual 11 Mid-Day Movers

Add Your Comment